May 18, 2009 Conference Call Michael Minogue, Chairman, President and CEO Robert Bowen, CFO (NASDAQ: ABMD) May 8, 2009 Exhibit 99.2 |
2 Legal Disclaimers Not FDA Approved, See Disclaimer Red Box Indicates This information includes forward looking statements including statements regarding the future financial performance, product development efforts, ABIOMED’s strategic operational initiatives, and market response to ABIOMED’s new products. ABIOMED’s actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with the development, testing and related regulatory approvals, competition, technological change, future capital needs, and other risks detailed in the Company’s filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of today’s date. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after today’s date or to reflect the occurrence of unanticipated events. IMPELLA® Pediatric, Implantable, Right Percutaneous are Not Available for Sale in the United States. AbioCor® II is not approved by the FDA for Sale in the United States |
3 Impella 2.5 510(k) Clearance 6/08 CE Impella Console CE Impella Pediatric Impella Right Percutaneous Intra-aortic Balloon 510(k), CE BVS Blood Pump FDA Approved, CE New Products & Regulatory Execution AB5000 Ventricle FDA Approved, CE Not FDA Approved, See Disclaimer Impella Cath Lab/ Percutaneous Placement PMA Supplement 4/09, CE iPulse FDA Approved, CE iPulse Surgical VAD Placement Impella 5.0 / LD 510(k) Clearance 4/09 CE |
1/14/09 Impella 510(k) US Launch FY09 = 521 Patients Q2*: June to Sept. 2008 • 100 patients in 4 months, 6 a week avg. • $6.2M US Q2 commercial revenue • @ 108 Hospitals • 35% reorder revenue Q3: Oct to Dec. 2008 • 160 patients, up 60%, 13 a week avg. • $6.7M US Q3, up 8% sequentially • Added 55 accounts @ 163 Hospitals, up 51% • 48% reorder revenue 4 (*US News & World Reports) Q4: Jan to March 2009 • 261 patients, up 63%, 22 a week avg. • $9.1M US Q4, up 37% sequentially • Added 66 accounts @ 229 Hospitals, up 40% • >50% reorder revenue Total Worldwide Impella revenue $10.6M Total Worldwide Impella revenue $8.8M Total Worldwide Impella revenue $11.2M |
5 5 Why we believe Impella is Superior to IABP Direct Heart Unloading…reducing O 2 demand on heart Supporting Coronary Flow…increasing O 2 supply to heart Increasing Cardiac Power…increasing O 2 supply to all organs, the highest correlate to decreasing mortality Impella IABP 5 |
6 Impella Technology … Validated in Studies |
7 Showcasing Impella Superiority Over IABP MACH II Impella Improves Ejection Fraction in AMI 3 Days % Pts. Improvement in Ejection Fraction (EF) 2% 5% 9% 13% 120 Days Impella 2.5 Standard of Care p<0.05 ISAR-SHOCK Impella Provides 5X Better Hemodynamic Support Than IABP in AMI Cardiogenic Shock (Seyfarth et al. American College of Cardiology, 2007) P<0.01 1.10 0.20 0.25 1.25 0.75 0.50 1.50 0 Impella IABP PAMI-II: No Benefit in Mortality or LV Function for IABP (n=211) (Stone et al, J ACC29:1459, 1997) Cardiac Power Output (n= 20) (n= 26) (Fincke R et al. JACC 2004 Vol 44, n2: 304-8) (Henriques et al. American College of Cardiology, 2007) Strongest Hemodynamic Correlate of Mortality Cardiac Power Output (n=189) |